Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)

American Heart Journal

Volumn 161, Issue 6, 2011, Pages 1171-1178

  Brouwers, Frank P ^a   Asselbergs, Folkert W ^a,b   Hillege, Hans L ^a   De Boer, Rudolf A ^a   Gansevoort, Ron T ^a   Van Veldhuisen, Dirk J ^a   Van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FOSINOPRIL; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVOR; TREATMENT OUTCOME; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; FOSINOPRIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 79958086577     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.03.028     Document Type: Article

References (22)

1. P. Farbom, B. Wahlstrand, and P. Almgren Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study Hypertension 52 2008 115 122
2. R. Pontremoli, G. Leoncini, and F. Viazzi Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension J Am Soc Nephrol 16 Suppl 1 2005 S39 S41
3. G.F. Diercks, A.J. van Boven, and H.L. Hillege Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study Eur Heart J 21 2000 1922 1927
4. H.L. Hillege, W.M. Janssen, and A.A. Bak Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity J Intern Med 249 2001 519 526 (Pubitemid 32823860)
5. F.W. Asselbergs, G.F. Diercks, and H.L. Hillege Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816 (Pubitemid 39473602)
6. I. Ford, H. Murray, and C.J. Packard Long-term follow-up of the West of Scotland Coronary Prevention Study N Engl J Med 357 2007 1477 1486 (Pubitemid 47572633)
7. J. Bosch, E. Lonn, and J. Pogue Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension Circulation 112 2005 1339 1346 (Pubitemid 41266730)
8. P. Jong, S. Yusuf, and M.F. Rousseau Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study Lancet 361 2003 1843 1848 (Pubitemid 36645177)
9. C. Lydakis, and G.Y. Lip Microalbuminuria and cardiovascular risk QJM 91 1998 381 391 (Pubitemid 28286837)
10. D.E. Weiner, and M.J. Sarnak Microalbuminuria: a marker of cardiovascular risk Am J Kidney Dis 42 2003 596 598 (Pubitemid 37048139)
11. J. Xu, W.C. Knowler, and R.B. Devereux Albuminuria within the "normal" range and risk of cardiovascular disease and death in American Indians: the Strong Heart Study Am J Kidney Dis 49 2007 208 216 (Pubitemid 46178394)
12. S.D. Solomon, M.M. Rice, and A. Jablonski Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial Circulation 114 2006 26 31 (Pubitemid 44305271)
13. J. Arnlov, J.C. Evans, and J.B. Meigs Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study Circulation 112 2005 969 975 (Pubitemid 41170264)
14. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788 (Pubitemid 37093919)
15. E. Ambrosioni, C. Borghi, and B. Magnani The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators N Engl J Med 332 1995 80 85
16. C. Torp-Pedersen, L. Kober TRACE Study Group. Trandolapril Cardiac Evaluation Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction Lancet 354 1999 9 12 (Pubitemid 29304295)
17. R. Bilous, N. Chaturvedi, and A.K. Sjolie Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med. 151 2009 11 14
18. M. Marre, M. Lievre, and G. Chatellier Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 328 2004 495
19. D.E. Rifkin, R. Katz, and M. Chonchol Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly Nephrol Dial Transplant 25 2010 1560 1567
20. S. Masson, R. Latini, and V. Milani Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure. Data from the GISSI-Heart Failure (GISSI-HF) trial Circ Heart Fail 3 2010 65 72
21. P.A. McCullough Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease Circulation 114 2006 6 7 (Pubitemid 44305267)
22. H.C. Gerstein, S. Yusuf, and J.F.E. Mann Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 2000 253 259 (Pubitemid 30068516)